Syncona Limited led a €80M Series B funding round for iOnctura, a European biopharma targeting hard-to-treat cancers.
Syncona Limited led a €80M Series B funding round for iOnctura, a European clinical-stage biopharmaceutical company focusing on hard-to-treat cancers. iOnctura's lead candidate, roginolisib, is a first-in-class PI3K delta inhibitor in Phase Ib for metastatic uveal melanoma. Syncona also launched Yellowstone Biosciences, which focuses on soluble bispecific TCR-based therapies for blood cancer and beyond, with a £16.5M Series A commitment.
June 20, 2024
3 Articles